Research can be 'bought,' but when that happens the money (or prestige) tends to pour from a political or business pitcher. Now, I'm beginning to think that fat couch potatoes have a money pitcher too, in this case, to tell them that it's okay to sit around eating and just lifting a few fingers every once in awhile.
Natural metals are proving very effective identifiers of diseased tissue and are even used as treatment carriers in today's nanotherapies. These compounds are known as theranostic agents because of their ability to both diagnose and deliver treatment to a tumor or other diseased site. Two Virginia universities have recently published the results of their theranostic discovery and its use for brain cancer treatment on animal models.
Every month more studies are published that demonstrate that if there is to be successful avoidance of, or limitation to, the ravages of Alzheimer's disease, intervention needs to begin as early as possible. Several suggest that treatments begin before Alzheimer's symptoms appear. One study, published online just yesterday in the Archives of Neurology, shows the benefits of doing such.
You've heard the commercials for allergy treatments; they all promise relief from the symptoms of allergies. But now, researchers from the University of Nottingham in the UK have found the secret to what causes a very common allergy - cat allergies. Their discovery could lead to a whole new class of drugs that attack allergies at their first point of contact, so that symptoms of allergy and asthma never develop at all.
The type of skin cancer known as melanoma has historically been one of the deadliest forms of cancer. Though a few drugs have helped extend the 5 and 10 year survival periods, news of two particular drugs presented at yesterday's annual meeting of the American Society of Clinical Oncology have sparked some real hope for the future.
Scientists from the Center for Alzheimer’s and Neurodegenerative Diseases at the University of Texas Southwestern Medical Center have discovered that the drug SAHA shows promise as a potential therapy for familial frontotemporal dementia (FTD). As yet, there is no treatment for the neurological disease, the second most common non-elderly dementia.